A report from Oppenheimer raises its FY11/12 EPS estimates to $1.50 and $1.67 on Thoratec THOR. It also reiterates its Outperform rating and $40 price target.
The report states, “3Q revenues of $102.6M (+13% y/y) were slightly below us ($104.8M) and consensus ($103.3M). THOR trimmed '11 sales guidance by $5-6M to $418-423M. The company is seeing slower near-term implant rates owing to capacity constraints at implant centers. Importantly, management comments echoed what we heard from the cardiology community at the recent HFSA meeting—the interest level among referring docs continues to build."
THOR closed yesterday at $34.89.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in